Maybe there is something to Affinium Pharmaceuticals’ new name. Last week the Toronto-based company, formerly known as Integrative Proteomics, announced that it had struck a deal valued at $30 million with Pfizer to comprehensively study and develop leads for an unspecified number of the big pharma’s target proteins. And on Monday of last week, the Cystic Fibrosis Foundation agreed to give Affinium and the Hospital for Sick Children in Toronto $5 million to identify potential drug targets for that disease.